Jacobs Levy Equity Management’s Aldeyra Therapeutics ALDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.43M | Buy |
634,156
+596,172
| +1,570% | +$2.28M | 0.01% | 583 |
|
|
2025
Q1 | $218K | Buy |
+37,984
| New | +$218K | ﹤0.01% | 1020 |
|
|
2024
Q4 | – | Sell |
-476,949
| Closed | -$2.57M | – | 930 |
|
|
2024
Q3 | $2.57M | Buy |
476,949
+295,864
| +163% | +$1.59M | 0.01% | 558 |
|
|
2024
Q2 | $599K | Buy |
181,085
+2,166
| +1% | +$7.17K | ﹤0.01% | 816 |
|
|
2024
Q1 | $585K | Buy |
+178,919
| New | +$585K | ﹤0.01% | 803 |
|
|
2023
Q1 | – | Sell |
-21,374
| Closed | -$149K | – | 950 |
|
|
2022
Q4 | $149K | Sell |
21,374
-260,462
| -92% | -$1.81M | ﹤0.01% | 916 |
|
|
2022
Q3 | $1.51M | Buy |
281,836
+47,166
| +20% | +$252K | 0.01% | 615 |
|
|
2022
Q2 | $936K | Buy |
+234,670
| New | +$936K | 0.01% | 767 |
|
|
2021
Q3 | – | Sell |
-43,069
| Closed | -$488K | – | 1027 |
|
|
2021
Q2 | $488K | Hold |
43,069
| – | – | ﹤0.01% | 864 |
|
|
2021
Q1 | $512K | Sell |
43,069
-254,763
| -86% | -$3.03M | ﹤0.01% | 860 |
|
|
2020
Q4 | $2.04M | Sell |
297,832
-8,002
| -3% | -$54.9K | 0.02% | 582 |
|
|
2020
Q3 | $2.27M | Buy |
305,834
+795
| +0.3% | +$5.89K | 0.02% | 498 |
|
|
2020
Q2 | $1.27M | Buy |
305,039
+260,076
| +578% | +$1.08M | 0.01% | 620 |
|
|
2020
Q1 | $111K | Buy |
44,963
+17,131
| +62% | +$42.3K | ﹤0.01% | 953 |
|
|
2019
Q4 | $162K | Buy |
+27,832
| New | +$162K | ﹤0.01% | 954 |
|